Integrated clinical experience with tolerogenic peptides

Area of Science:

• Immunology
• Allergology
• Pharmacology

Background:

• Allergen-specific immunotherapy aims to desensitize patients to allergens.
• Peptide-based approaches target specific T cell epitopes for improved safety and efficacy.
• Clinical development of targeted peptide therapies for common allergies like cat and ragweed is ongoing.

Purpose of the Study:

• To evaluate the clinical activity and safety of peptide-derived immunotherapy for cat (Fel d 1) and ragweed (Amb a 1) allergies.
• To investigate the mechanism of action and potential side effects of the investigational treatment.
• To assess the impact of therapy on allergic immune responses.

Main Methods:

• Selection of five peptides (two from Fel d 1, three from Amb a 1) based on T cell epitope mapping.
• Administration of peptide regimens (75-750 microg) in 4-6 doses over 2-4 weeks to over 2,000 patients.
• Monitoring of clinical activity, immediate hypersensitivity, and allergic symptom pathways.

Main Results:

• Clinical activity demonstrated across various dose regimens, with higher doses showing greater efficacy.
• Immediate hypersensitivity to treatment peptides was rare and manageable through patient screening.
• A histamine-mediated, IgE-independent pathway for allergic symptoms was identified, more pronounced in cat allergies.
• Symptoms could be ameliorated with H1 blockers, and the seasonal rise in allergen-specific IgE was blunted.

Conclusions:

• Peptide-derived immunotherapy for cat and ragweed allergies is clinically active and generally well-tolerated.
• The treatment appears to modulate allergic responses through a non-IgE-dependent mechanism.
• Further long-term studies are warranted to monitor immune responses, including antibody levels and T cell proliferation.